Parkinson’s Disease
-
GSK and Vesalius Enter Multi-Target Strategic Alliance to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Congratulations to GSK and Vesalius Therapeutics!
-
【Urgent Request】European and American biotech companies are interested in licensing drugs for PD, AD and other CNS diseases
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
